Navigation Links
The Diabetes Series 2008: Experts Speak About Developing Diabetes Therapeutics
Date:2/25/2008

SAN DIEGO, Feb. 25 /PRNewswire/ -- Speid & Associates, a San Diego-based regulatory affairs and drug development consultancy, is hosting a six session Webinar series on diabetes and related metabolic diseases during the months of March and April. Speakers will include former Food and Drug Administration officials Dr. Alexander Fleming and Dr. Ray Lipicky, as well as a distinguished list of other guest speakers and panelists.

Researchers and companies involved in diabetes therapeutic development are finding a complex array of possible targets across diabetes (both type 1, type 2), the metabolic syndrome, and the complications and causes of diabetes. This translates into a complex pathway for therapeutic development and registration with many potential pitfalls along the way. The webinar series will promote discussion on the inter-related issues of diabetes/metabolic therapeutic development and registration.

Dr. Speid said, "I am delighted that the series will feature such a stellar list of speakers, to address these important topics and issues." Dr. Alexander Fleming, ex-FDA (formerly headed diabetes drug review) said, "There is no more active and controversial therapeutic development area than for diabetes drugs. I look forward to discussing the implications of the ACCORD trial and a number of other timely topics."

For many years, Dr. Ray Lipicky headed FDA's Division of Cardiorenal Drug Products. Among his many drug approvals was the first and essentially only approval of treatments for a diabetic complication. The participation of Drs. Lipicky and Fleming in this series mirrors the convergence of cardiovascular and metabolic therapeutics at multiple levels -- pathophysiology, drug targets, trial design, and clinical disciplines.

Speid & Associates, Inc. is a regulatory affairs and drug development consultancy based in San Diego, Calif. The firm, founded in 2004 by Dr. Lorna Speid, Ph.D., assists life science companies at various stages in the drug development process. Speid's services, which vary from building global regulatory strategies to conducting due diligence for possible drug acquisitions, save large and small pharmaceutical firms from costly mistakes. Dr. Speid began her career as a pharmacist in the UK, after which she completed a Ph.D. at the Centre for Medicines Research International, into the Safety Assessment of Medicines, Pre and Post Marketing. Before forming her own consultancy, Dr. Speid worked for Sanofi Winthrop in the UK, Ciba Geigy and Novartis in Switzerland (HQ). Dr. Speid also worked for a number of small pharmaceutical companies, two of them at the Vice President level. For more information, see http://www.sndtm.com.

Further information regarding the webinar series is available at: http://www.sndtm.com/webinar.html as well as sign up instructions.

Telephone 858 793 1295. Email lspeid@sndtm.com.


'/>"/>
SOURCE Speid & Associates, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Vaccines are Likely to Cause Insulin Dependent Diabetes in Over 2% of Children With a Strong Family History of Insulin Dependent Diabetes, New Data Indicates
2. Good Neighbor Pharmacy(R) Ironman Competitor Inspires Individuals with Diabetes to Live Without Limits
3. Genaera Corporation to Participate in Diabetes and Obesity Panel at RBC Capital Markets Healthcare Conference
4. GlaxoSmithKline Responds to JAMA Article on the ICES Thiazolidinediones and Cardiovascular Outcomes in Older Patients with Diabetes
5. Novo Nordisk Applauds Adoption of World Diabetes Day Resolutions by U.S. Congress
6. International Diabetes Experts Call for Stepped-Up Action and Shared Responsibility to Curb Rising Global Diabetes Epidemic and Impact
7. World Think Tank on Type 1 Diabetes Meets in Miami
8. New Web Site Tools Help Alleviate Stress Associated with Caring for Children with Diabetes During the Holidays
9. Actress Aida Turturro Tells Americans to Start Now to Talk With Their Healthcare Provider About Taking Control of Their Diabetes
10. SemBioSys to present insulin data at the Seventh Annual Diabetes Technology Meeting
11. John Timberlake, Valeritas Executive Vice President and General Manager, Named Executive of the Year by the Diabetes Foundation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... ... 2017 , ... Delpor, Inc. (Delpor), a biotechnology company focused on drug delivery, ... Health (NIMH) for the further advancement of the company’s 3-month olanzapine product ( DLP-119 ... to deliver therapeutic levels of olanzapine for a period of 3 months., “We are ...
(Date:2/24/2017)... , Feb. 24, 2017 Symic Bio, a ... a new category of therapeutics, announced today the completion ... in peripheral artery disease. The trial will evaluate the ... therapeutic, in the reduction of restenosis following angioplasty. ... development milestone for SB-030," said Nathan Bachtell , ...
(Date:2/24/2017)... 23, 2017 China Biologic Products, Inc. (NASDAQ: CBPO) ... biopharmaceutical company in China, today announced its financial results for ... Fourth Quarter 2016 Financial Highlights ... 21.7% in RMB terms, or increased by 13.6% in USD ... quarter of 2015. Gross profit increased by ...
(Date:2/23/2017)... 23, 2017 ... per share data, unaudited)Three Months Ended December 31,Twelve Months ... $         ...   89026%Aldurazyme Net Product Revenue ... Net Product Revenue  756025%297303(2)%Vimizim Net ...
Breaking Biology Technology:
(Date:2/8/2017)... -- Report Highlights The global biosurgery market ... in 2016 at a compound annual growth rate (CAGR) ... - An overview of the global market for biosurgery. ... 2015 and 2016, and projections of compound annual growth ... on the basis of product type, source, application, and ...
(Date:2/7/2017)... Zimmer Biomet Holdings, Inc. (NYSE and SIX: ... at the LEERINK Partners 6th Annual Global Healthcare Conference ... February 15, 2017 at 10 a.m. Eastern Time. ... be accessed at http://wsw.com/webcast/leerink28/zbh .  The webcast will ... Biomet,s Investor Relations website at http://investor.zimmerbiomet.com . ...
(Date:2/6/2017)... Feb. 6, 2017 According to Acuity ... driving border authorities to continue to embrace biometric ... are 2143 Automated Border Control (ABC) eGates and ... at more than 163 ports of entry across ... 2016 achieving a combined CAGR of 37%. APC ...
Breaking Biology News(10 mins):